87 related articles for article (PubMed ID: 15648949)
41. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Kandalaft LE; Motz GT; Duraiswamy J; Coukos G
Cancer Metastasis Rev; 2011 Mar; 30(1):141-51. PubMed ID: 21298574
[TBL] [Abstract][Full Text] [Related]
42. Tolerance signaling molecules.
Clark DA
Chem Immunol Allergy; 2005; 89():36-48. PubMed ID: 16129951
[TBL] [Abstract][Full Text] [Related]
43. Tumors hijack fetal enzyme, escape killer T cells.
Schepers K; Schumacher TN
Nat Med; 2003 Oct; 9(10):1253-4. PubMed ID: 14520367
[No Abstract] [Full Text] [Related]
44. Overcoming tumor immune evasion with an unique arbovirus.
Lyday B; Chen T; Kesari S; Minev B
J Transl Med; 2015 Jan; 13():3. PubMed ID: 25592450
[TBL] [Abstract][Full Text] [Related]
45. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R
Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380
[TBL] [Abstract][Full Text] [Related]
46. [A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].
Van den Eynde B
Bull Mem Acad R Med Belg; 2003; 158(7-9):356-63; discussion 364-5. PubMed ID: 15132006
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Muller AJ; DuHadaway JB; Donover PS; Sutanto-Ward E; Prendergast GC
Nat Med; 2005 Mar; 11(3):312-9. PubMed ID: 15711557
[TBL] [Abstract][Full Text] [Related]
48. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
49. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
Gajewski TF
Curr Opin Investig Drugs; 2004 Dec; 5(12):1279-83. PubMed ID: 15648949
[TBL] [Abstract][Full Text] [Related]
50. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2326s-2330s. PubMed ID: 16609053
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
Poggi A; Zocchi MR
Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
